Gynecology Drugs Global Market Report 2022: A $33.21 Billion Market in 2026 – ResearchAndMarkets.com – Yahoo Finance
DUBLIN, April 08, 2022–(BUSINESS WIRE)–The "Gynecology Drugs Global Market Report 2022: By Therapeutics, By Indication, By Distribution" report has been added to ResearchAndMarkets.com's offering.
The global gynecology drugs market is expected to grow from $24.68 billion in 2021 to $26.36 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%.. The growth is mainly due to the increase in gynecological disorders among women and rising cases of gynecological cancer. The market is expected to reach $33.21 billion in 2026 at a CAGR of 5.9%.
North America was the largest region in the gynecology drugs market in 2021. Asia Pacific is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The rise in number of women suffering from ovarian cancer would drive the growth of the global gynecological drugs market. For instance, according to Globocan, it is estimated that the global incidence of ovarian cancer will increase to 434,184 by 2040. The increasing incidence of ovarian cancer would boost the market for gynecological drugs in the forecast period.
Alternative treatment methods and natural remedies are increasingly becoming popular globally which is expected to have a negative impact on the revenues of gynecological drugs companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses range of techniques and treatments for gynecological cancer. Many herbs used in Ayurveda have anti-cancer properties, example Curcumin, Holy Basil are said to inhibit the growth of cancerous cells and Ayurvedic gynecological procedures like Agnikarma helps treat cervical erosion. This growing adoption of alternative treatments is expected to have a negative impact on the growth of the market.
Drug manufacturers are investing in developing personalized cancer vaccines, including gynecological cancers, and few have reached clinical trial phases. Pharmaceutical companies are combining genetic sequencing and precision medicine to create new drug therapies and cancer treatments that are designed to treat specific patients. For instance, in September 2021, scientists from the University of Oxford and the Ludwig Institute for Cancer Research designed a two-dose therapeutic cancer vaccine using Oxford's viral vector vaccine technology. In 2019, Moderna announced the result from the ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors. The results were positive when mRNA personalized cancer vaccine (PCV) mRNA-4157, given alone or in combination with Merck pembrolizumab (KEYTRUDA). Currently the vaccine is in phase 2 clinical trial.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider gynecology drugs market, and compares it with other markets.
The market characteristics section of the report defines and explains the market
The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth
Market segmentations break down market into sub markets
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
The gynecology drugs market section of the report gives context. It compares the gynecology drugs market with other segments of the gynecology drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, gynecology drugs indicators comparison
Hoffmann-La Roche Ltd.
Merck & Co.
Ferring Holding SA
Johnson & Johnson
Eli Lilly and Company
For more information about this report visit https://www.researchandmarkets.com/r/yzoj5f
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005168/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Tilray (NASDAQ: TLRY), a Canadian cannabis company, saw its shares drop 10.1% on Thursday. Investors likely took profits after Tilray got a bump on Wednesday following its third-quarter earnings report, which contained mostly good news. More importantly, Tilray reported net income of $52.5 million compared to a loss of $273.52 million in the same period last year, with earnings per share (EPS) of $0.09 compared to a loss of $1.03 per share.
Semiconductor stocks have soared over the last few quarters, driven higher by robust demand for chips amid a global supply shortage. “On Wednesday afternoon we learned of a sudden negative shift in demand signals from a wide swath of computer, consumer, and communications OEMs [original equipment manufacturer] to at least some of their semi suppliers,” he wrote in a research note. While a single-quarter adjustment or a temporary headwind was possible, he was concerned that “a combination of just enough demand destruction and just enough additional supply is leading to a traditional cyclical downturn.”
These income stocks, with yields ranging from 2.3% to 7.1%, can put historically high inflation in its place.
Shares of Ford Motor Company (NYSE: F) stock fell hard in afternoon trading Thursday, down 4.3% as of 1:20 p.m. ET. You can blame Barclays Capital for that. The British banker downgraded Ford shares to equal weight this morning, you see, and slashed its price target on Ford by 26%, to just $17 per share, as StreetInsider.com reported.
The big shareholder groups in GameStop Corp. ( NYSE:GME ) have power over the company. Generally speaking, as a company…
The Iraq war doesn't have many parallels to Russia's invasion of Ukraine, other than perhaps global unpopularity. But there seems to be at least one parallel — how stocks have behaved.
The macro-economic picture is deteriorating fast and could push the U.S. economy into recession as the Federal Reserve tightens its monetary policy to tame surging inflation, BofA strategists warned in a weekly research note. The Federal Reserve on Wednesday signalled it will likely start culling assets from its $9 trillion balance sheet at its meeting in early May and will do so at nearly twice the pace it did in its previous "quantitative tightening" exercise as it confronts inflation running at a four-decade high. In terms of notable weekly flows, BofA said emerging market equity funds enjoyed the biggest inflow in ten weeks at $5.3 billion in the week to Wednesday while emerging market debt vehicles attracted $2.2 billion, their best week since September.
Since 2020, many investors have developed exceptionally high expectations for the stock market because of the jaw-dropping performances of some companies. Fulgent Genetics (NASDAQ: FLGT), for example, gave investors over 763% returns from the start of 2020 to March 2021. Roku (NASDAQ: ROKU) has certainly been an underwhelming performer, falling 68% over the past year.
It can be a growth stock or a value stock. One is a pharmaceutical company making one of the world's most in-demand products today. Pfizer's (NYSE: PFE) earnings took off, thanks to its coronavirus vaccine.
Dividend stocks may be boring compared to high-flying technology stocks, but boring can be good in a market that has been so wild and unpredictable lately. One of the best places to look for good dividend stocks is the financial sector, for a few reasons. Here are three cheap dividend stocks to provide some ballast to your portfolio.
Shares of Boeing Co. slipped 0.7% in morning trading Friday, after reports that a Boeing 757 cargo jet broke in half while landing. The stock was the biggest decliner among Dow Jones Industrial Average components. A Boeing 757 operated by package delivery company DHL detected a hydraulic system failure soon after take off from the San Jose, Costa Rica airport on Thursday, and on its return slid off the runway and broke in half,
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see AbbVie Inc…
Nvidia has become the gold standard in artificial intelligence (AI). From supercomputing hardware to subscription software, it provides everything a business needs to develop and run AI applications at scale. Not surprisingly, Nvidia is also the most valuable semiconductor company in the world.
The one big concern investors have about coronavirus-vaccine giant Moderna (NASDAQ: MRNA) is this: a potential drop in revenue. Moderna's only commercialized product right now is its coronavirus vaccine.
While many names in the EV sector were also dropping in the market session, Nio shares were leading the declines. Chinese media outlet 36Kr reported on Thursday that a high-ranking executive for Nio's autonomous driving unit was leaving the company. Zhang started with Nio in 2015 and most recently reported directly to Nio CEO William Li.
One of the strongest balance sheets imaginable is a key reason Real Money Columnist Stephen 'Sarge' Guilfoyle likes this stock.
(Bloomberg) — Don’t be fooled by the stock market’s rapid-fire reaction to the news. It’s just the beginning of the first real slog in years, one that will hand a comeuppance to passive investors who once thought the only way for prices to go was up.Most Read from BloombergCanada to Ban Foreigners From Buying Homes as Prices SoarMocked as ‘Rubble’ by Biden, Russia’s Ruble Roars BackPutin Army Regroups for Ukraine Showdown After Invasion SetbackRussia Sidesteps Sanctions to Supply Energy to Will
In this article, we discuss 10 stocks that US senators are selling. If you want to see more stocks that were recently sold by US senators, click 5 Stocks US Senators Are Selling. Investors often seek to replicate the returns of House members and senators, since it is usually assumed that politicians are privy to […]
Workplace automation company UiPath (NYSE: PATH) recently reported its fiscal 2022 fourth-quarter earnings, for the period ending Jan. 31. Investors punished the stock, sending it to new lows. UiPath burst onto the scene with a hot initial public offering (IPO) in April 2021, a time when the markets were euphoric.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to…